GenEditBio Scientist Receives Excellence in Research Award at the 28th Annual Meeting of the American Society of Gene and Cell Therapy 2025
[May 16, 2025] – GenEditBio Limited (“GenEditBio”), a biotechnology start-up company focusing on genome-editing therapeutic solutions through the discovery of novel Cas nuclease and the development of safe and efficient cargo delivery platforms, today announced that one of the abstracts in collaboration with the Eye & ENT Hospital of Fudan University was selected for the Excellence in Research Award at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), New Orleans, Louisiana, USA, May 13-17, 2025.
Mr Zihua JIANG, Team Lead of the Novel Delivery platform and a first-year doctoral student at Karolinska Institutet, was awarded the Excellence in Research Award for his oral presentation entitled “Engineered Protein Delivery Vehicles Enable Single Intrastromal CRISPR-Cas9 Therapy for TGFBI Corneal Dystrophies with High Efficacy and Safety: A Comprehensive Preclinical Assessment in Non-Human Primates”. This highly competitive honor, awarded by the ASGCT–the largest professional organization dedicated to gene and cell therapy–recognizes the top 15 abstracts submitted by students and fellows out of nearly 2000 submissions.
“We congratulate Zihua for this remarkable recognition of the teamwork”, said Zongli ZHENG, PhD, Co-Founder and Chairman of GenEditBio and mentor of the awardee, “The work not only exemplifies research excellence but also underscores GenEditBio’s commitment to pioneering world-class research and advancing innovative genome-editing therapies”. “This prestigious award highlights how partnership between industry and university can work together to drive the development of innovative therapy”, said Tian ZHU, PhD, Co-Founder and CEO of GenEditBio.
“We congratulate Zihua for this outstanding achievement”, said Xingtao ZHOU, MD, PhD, Professor and President of the Eye & ENT Hospital of Fudan University, “The preclinical success in non-human primates paves the way for clinical translation, offering opportunities for a one-time, curative approach for corneal dystrophies”. “The teamwork bridges the critical gap between CRISPR therapeutic potential and the clinical implementation for corneal disorders, offering a modular platform adaptable to other anterior segment diseases”, said Jiaxu HONG, MD, PhD, Professor and Consultant Physician of the Eye & ENT Hospital of Fudan University.
Mr Zihua JIANG (first right) receives the Excellence in Research Award during the George Stamatoyannopoulos Lecture at ASGCT 2025 (Photo: Bang WANG)
About GenEditBio
Established in 2021 and headquartered in Hong Kong, China, GenEditBio is a gene therapy start-up company with an overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed “DNA surgery”) with high safety profile, unmatched precision, and affordable access for genetic diseases with unmet needs. The Company’s core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing lipid nanoparticle (LNP) and engineered protein delivery vehicle (PDV). We have research laboratories and supporting offices in Hong Kong, Beijing, and Boston. GenEditBio is financially backed by top-tier life science investors, including Qiming Venture Partners, Fangyuan Capital, Center Biotherapeutics, Lumosa Therapeutics, HKSTP Venture Fund, and other investors.
Contact
